Advicenne: shares up, Sibnayal reimbursed in France

(CercleFinance.com) - Advicenne is up in the stock market this Monday after announcing that Sibnayal will be reimbursed by France's public health insurance in the treatment of distal renal tubular acidosis (dRTA).


The pharmaceutical company's shares climbed almost 7% in a Paris market showing a marked decrease (-1.5%) due to the concerns linked to the propagation of the Omicron variant in Europe.

Advicenne specifies in a press release that the opinion of France's Transparency Committee of the French National Authority for Health makes Sibnayal the only reimbursed medicine for the treatment of dRTA.

Distal renal tubular acidosis is a rare disease characterised by the kidney's inability to excrete acid from the metabolism, which can lead to multiple complications, from stunted growth to renal failure.

Copyright (c) 2021 CercleFinance.com. All rights reserved.